Next Article in Journal
Comparing Obstetrical Outcomes Between Attention Deficit Hyperactivity Disorder and Attention Deficit Disorder: A Population-Based Studys
Previous Article in Journal
Transcutaneous CO2 Measurement in an Adult Long-Term Ventilation (LTV) Service
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 14
Issue 12
10.3390/jcm14124141
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Somatostatin Receptor Scintigraphy in Autoimmune Syndrome Induced by Silicone Breast Implants: Pre- and Postexplantation Findings

by
Luz Kelly Anzola
1,2,*,
Sara Ramirez
3,
Sergio Moreno
4,
Camilo Vargas
5,
Sebastian Rojas
3 and
José Nelson Rivera
6
1
Nuclear Medicine Unit, Clinica Reina Sofia, Bogotá 110121, Colombia
2
Nuclear Medicine Unit, Clinica Universitaria Colombia, Bogotá 110931, Colombia
3
Fundación Universitaria Sanitas, Bogotá 110131, Colombia
4
Clinical Research Institute, Universidad Nacional de Colombia, Bogotá 111321, Colombia
5
Medicina Nuclear Sanitas Palermo, Bogotá 111311, Colombia
6
Internal Medicine Department, Clinica Reina Sofia, Bogotá 110121, Colombia
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2025, 14(12), 4141; https://doi.org/10.3390/jcm14124141
Submission received: 10 May 2025 / Revised: 7 June 2025 / Accepted: 10 June 2025 / Published: 11 June 2025
(This article belongs to the Special Issue Selected Papers from the 4th International Conference on Inflammation and Infection Imaging)
Browse Figures
Versions Notes

Abstract

:
Background: Silicone breast implants have been linked to autoimmune/inflammatory syndrome induced by adjuvants (ASIA). This study evaluates the role of 99mTc-HYNIC-TOC somatostatin receptor scintigraphy in assessing somatostatin-mediated inflammation and the impact of explantation on inflammatory activity. Methods: Fifty patients with silicone breast implants and symptoms suggestive of ASIA were evaluated. Pre- and postexplantation imaging was performed using 99mTc-HYNIC-TOC scintigraphy. Matthews correlation coefficients quantified associations between clinical symptoms and imaging findings, and autoantibody profiles were analysed. Results: Scintigraphy identified a significant uptake in organs associated with autoimmune symptoms, particularly joints and salivary glands. Strong correlations were found between imaging findings and symptoms, including knee pain (MCC = 0.81) and sicca syndrome (MCC = 0.96). Explantation resolved abnormal uptake in the surgical bed, though variable uptake persisted in other organs, reflecting systemic inflammatory heterogeneity. Autoantibody analysis revealed positivity in 66% of patients, with antinuclear antibodies being most frequent (30%). Conclusions: 99mTc-HYNIC-TOC scintigraphy effectively evaluates organ-specific inflammation in ASIA. Explantation reduces localized inflammation but does not consistently address systemic autoimmune responses. Larger prospective studies are needed to validate these findings and improve management strategies for ASIA.

1. Introduction

The term “autoimmune/inflammatory syndrome induced by adjuvants” (ASIA), which emphasizes the role of environmental factors in the development of immune-mediated diseases, was introduced by Shoenfeld in 2011 [1]. He identified four conditions sharing similar signs and symptoms, all linked to prior exposure to an adjuvant: silicone-induced disease, Gulf War syndrome, macrophagic myofasciitis syndrome, and postvaccination phenomena. In genetically susceptible individuals, exposure to environmental factors such as infections, toxins, and drugs can trigger not only the onset of immune-mediated conditions but also influence their clinical manifestations [2]. Environmental agents with immune adjuvant effects, including silicone, aluminium, vaccines, and infections, have long been recognized. These adjuvants have been shown to induce autoimmunity in various animal models and may trigger autoinflammatory diseases in humans [3]. An immunologic adjuvant is defined as a substance that enhances antigen-specific immune responses without eliciting a response on its own [4]. The adjuvant effect operates through mechanisms affecting both innate and adaptive immunity; enhancing the activities of dendritic cells, lymphocytes, and macrophages; increasing local reactions to antigens; and promoting the release of chemokines and cytokines from T-helper and mast cells [5].
Over the past two decades, increasing evidence has linked the presence of silicone implants to subsequent autoimmune-related complications [6]. Studies suggest that while some patients develop postexposure autoimmune phenomena such as ASIA, others remain unaffected [7]. The identified at-risk groups for developing ASIA after receiving silicone implants include individuals with prior autoimmune reactions to adjuvants (e.g., vaccines, implants), those with established autoimmune conditions (e.g., Hashimoto’s disease, Graves’ disease, rheumatoid arthritis), individuals with a history of allergic or atopic disorders (e.g., eczema, pollen allergy, drug allergy), and those genetically predisposed to autoimmunity (e.g., HLA-DR4, HLA-DRB1) [8]. Silicone breast implants (SBIs) were initially believed to be durable; however, it was later discovered that the implant sheath can degrade over time, allowing silicone to migrate into surrounding tissues [9]. Yu et al. estimated that silicone diffuses at approximately 300 mg per year [10]. The adverse effects in patients with SBIs are extensive and include local complications such as lymphadenopathy, skin lesions, and pericapsular chronic inflammation [11]. Additionally, the direct impact of silicone on cellular immunity may lead to delayed-type hypersensitivity reactions involving Th1/Th17 cells, resulting in systemic symptoms associated with inflammatory and autoimmune diseases. T cells surrounding the silicone capsule often produce interleukin-17, interleukin-6, interleukin-8, and other growth factors [12]. The adjuvant effects on the humoral immune system are evidenced by increased levels of anti-collagen autoantibodies [13], elevated antinuclear antibodies (ANAs), and increased IL-2 levels in patients with SBIs, along with findings from animal models showing elevated anti-DNA antibodies [14]. Interest in the health effects of SBIs has resurfaced in the past decade because of reports of BI-associated anaplastic large-cell lymphoma (BIA-ALCL), desmoid tumours dependent on a periprosthetic capsule, and associations with autoimmune diseases [15]. Recent guidelines emphasize the importance of assessing antithyroid antibodies, rheumatoid factor, the erythrocyte sedimentation rate (ESR), immunoglobulin levels, and C-reactive protein as part of the preoperative evaluation to identify patients predisposed to developing autoimmune disorders or those with subclinical autoimmune diseases [16]. The detection of ANAs associated with Sjögren’s syndrome, the most common autoimmune condition linked to SBIs, is also recommended [17]. While the role of molecular imaging in this context has not been extensively evaluated, its potential in detecting inflammation related to autoimmune conditions is noteworthy. Advances in imaging technologies have introduced promising tools for diagnosing and monitoring these clinical conditions. Examples include macrophage CD206 receptors radiolabelled with 99mTc-Tilmanocept for diagnosing active rheumatoid arthritis [18], interleukin-2 radiolabelled with 99mTc-HMPAO for identifying active Crohn’s disease [19], and 2-deoxy-18F-fluoro-9-β-D-arabinofuranosylguanine for imaging T-cell activation [20]. Additionally, researchers have explored the use of radiolabelled somatostatin (SST) receptor 2 (SSTR 2) for detecting Sjögren’s syndrome and rheumatoid arthritis [21,22,23], among other conditions. The high diagnostic accuracy of these analogues stems from the strong binding affinity of SSTRs for their five receptor subtypes, which are expressed in various cells, including lymphocytes, monocytes, and inflammatory cells [24,25]. SST acts as a regulatory hormone that influences several physiological processes and plays a significant role in inflammatory responses. Clinical applications of radiolabelled SST analogues have yielded significant results in evaluating disease activity, prognosis, and therapeutic response in chronic inflammatory diseases [26,27]. Molecular imaging targeting SSTRs is a promising diagnostic tool for identifying active inflammation across various disorders and provides unique in vivo histopathological insights into cell-mediated inflammatory processes [22]. Recent studies have confirmed the ability of SSTR scintigraphy to localize active inflammation in both symptomatic and asymptomatic joints, as well as extra-articular sites such as salivary glands, demonstrating its potential in assessing conditions such as Graves’ ophthalmopathy, Sjögren’s disease, and rheumatoid arthritis [21,28,29,30]. Understanding how SBIs can provoke autoimmune responses is essential, as the immune reaction to silicone, although generally benign, may exacerbate underlying conditions in susceptible individuals. This underscores the necessity for personalized patient counselling and thorough risk assessment.
The primary objective of this study was to describe the pattern of uptake of SSTR scintigraphy in a cohort of patients with autoimmune symptoms and SBIs. The secondary objective was to describe findings from pre- and postexplantation studies in a small cohort of patients. We hypothesized that 99mTcHYNIC-TOC receptor scintigraphy can be used to identify organs with SST-mediated inflammation in patients with SBIs presenting with autoimmune symptoms.

2. Materials and Methods

2.1. Study Design

This study involved a descriptive analysis of 50 individuals with suspected ASIA associated with SBIs. An analytical cross-sectional study was conducted with retrospective data to describe the pattern uptake of radiolabelled SST 99mTcHYNIC-TOC scintigraphy. The study recruited participants from the nuclear medicine department from January 2019 to November 2023. A subset of seven patients underwent postexplantation scintigraphy, allowing for a comparison of pre- and postexplantation imaging findings. This research was approved by the hospital’s Ethics Committee (approval number: 2293-23 CEIFUS). Owing to the retrospective nature of the analysis, the requirement for written informed consent from the patients was waived.

2.2. Study Population

A nonprobabilistic consecutive sampling method was used; patients with SBIs and ASIA symptoms were referred by the clinician to the nuclear unit of the institution to assess inflammatory activity by using radiolabelled SSTR scintigraphy. All patients presented with anamnestic or clinical presentations of possible autoimmune conditions, and serological markers of immunological disease were obtained. All patients underwent 99mT-HYNIC-TOC scintigraphy.

2.3. Radiopharmaceutical

99mTcHYNIC-TOC was prepared in the radiopharmaceutical department from a commercially available kit (Tektrotyd®, POLATOM, Otwock, Poland) in accordance with the manufacturer’s instructions. Briefly, freshly eluted 99mTcO4- (740 MBq) in a 0.9% NaCl solution (pH 7) was added to vials containing HYNIC-Tyr3-octreotide (20 µg), tricine, and EDDA, mixed and incubated at 80 °C for 30 min according to existing recommendations [30].

2.4. Imaging Procedures

99mTcHYNIC-TOC Scintigraphy

Patients were intravenously injected with 99mTcHYNIC-TOC. The injected dose was standard 370 MBq. Planar and SPECT images were acquired using a dual-head gamma camera (Infinia, GE Healthcare, Milwakee, WI, USA) equipped with double-head, high-resolution, low-energy parallel hole collimators. Planar images of the head, neck, and joints were acquired for 10 min starting 3 h after intravenous injection of the radiotracer in a 512 × 512 matrix. The SPECT study was performed using 120 projection images over a 360° rotation, with 20 s per projection in a 128 × 128 matrix. Transaxial, coronal, and sagittal tomograms were reconstructed using a Butterworth filter and the ordered subset expectation maximization (OSEM) algorithm (two iterations, 10 subsets). ×100.

2.5. Image Analysis

The 99mTcHYNIC-TOC images were analysed by two observers (KA and SR) who were independent of each other and blinded to the clinical details. Analysis was performed using a previously proposed method (22). We did not consider the hips because of possible artefacts due to high bladder activity. The 99mTcHYNIC-TOC images were analysed qualitatively via calf uptake as a reference background. Uptake greater than calf uptake was considered abnormal, according to previous reports. To compare the data from the 7 patients who underwent explantation, we used the semiquantitative analysis reported by our group in previous studies (0, 1, 2, 3, and 4 compared with calf) [30].

2.6. Statistical Analysis

Patient demographics and clinical characteristics, including frequencies, percentages, means, and medians, were summarized using descriptive statistics. The associations between clinical symptoms and scintigraphic findings were evaluated using Matthews correlation coefficients. The pre- and postexplantation scintigraphic results were compared via paired analysis of seven patients who underwent repeat imaging following explantation. All the statistical analyses were performed using Stata 14.2 SE.

3. Results

Data were collected from 50 participants with SBIs who exhibited ASIA symptoms, with a mean age of 45.5 years (range: 24–67 years). Seven patients underwent explantation, followed by 99mTcHYNIC-TOC scintigraphy at a median of 18 months postsurgery. The demographic characteristics of the participants are summarized in Table 1.
The frequency of symptoms, which included thyroid dysfunction, periorbital fat changes, sicca, carpal and knee pain, and neurological symptoms, along with the corresponding findings from 99mTcHYNIC-TOC scintigraphy, are illustrated in Figure 1. The most frequently reported symptoms were associated with carpal and knee pain and sicca syndrome, which were correlated with the most frequent and highest abnormal uptake observed via HYNIC-TOC scintigraphy.
The correlations between reported symptoms and scintigraphic findings are presented in Table 2, highlighting the strongest associations between knee pain and sicca symptoms with positive scintigraphic results in the corresponding regions. These relationships were quantified by Matthews correlation coefficients of 0.81 and 0.92, respectively.
The distribution of specific antibodies detected in 31 out of 50 patients with SBIs and autoimmune-like symptoms is illustrated in Figure 2. The data highlight a predominance of ANAs among the identified antibodies, accounting for 30% of positive cases, followed by lupus anticoagulant (Russell, 14%); the group categorized as “others” includes antibodies that were detected at very low frequencies and, for data management purposes in the pie chart, were consolidated into a single category.
A semiquantitative analysis of findings in seven patients before and after explantation is provided in Figure 3, while details of the frequency of improvements observed in 99mTcHYNIC-TOC scintigraphy postsurgery are provided in Table 3.
Notably, all explanted patients exhibited no abnormal uptake of 99mTcHYNIC-TOC in the surgical bed. However, the postoperative patterns in the other evaluated organs varied. Thyroid uptake remained unchanged in five of the seven patients, whereas joint findings improved in three patients and remained stable in another three patients. Similarly, salivary gland findings improved in three patients, with four remaining stable. Notably, all but one patient tested positive for autoantibodies associated with autoimmune conditions (Figure 4).

4. Discussion

This study evaluated, for the first time, the characteristic uptake patterns of 99mTcHYNIC-TOC scintigraphy in patients with SBIs and autoimmune-like symptoms. The study confirmed significant scintigraphic uptake in organs associated with reported autoimmune symptoms, particularly in the joints and salivary glands. The findings revealed strong correlations between clinical symptoms, such as knee pain and sicca syndrome, and abnormal scintigraphic uptake in the corresponding regions, with Matthews correlation coefficients of 0.81 and 0.96, respectively. Additionally, the comparative analysis of pre- and postexplantation imaging demonstrated that explantation effectively resolved abnormal uptake in the surgical bed in all patients, with high variability in uptake changes across other organs, such as the thyroid, joints, and salivary glands, which underscores the heterogeneity of the inflammatory response associated with ASIA syndrome.
A considerable proportion of patients with silicone-related disease fulfil the diagnostic criteria for fibromyalgia [31], undifferentiated connective tissue disease [32], and sarcoid-like disease [33]. Additionally, many of these patients exhibit well-defined systemic autoimmune diseases, including Sjögren’s syndrome, rheumatoid arthritis, systemic sclerosis, antiphospholipid syndrome, and various forms of vasculitis [34]. These underlying autoimmune processes explain commonly reported symptoms, such as chronic fatigue, early-onset arthritis (observed in more than 90% of cases), myalgias (affecting up to 90% of patients), sicca symptoms (present in the majority of cases) [15], and severe neurological manifestations, which occur in 30–40% of patients. In the present cohort, the most frequent symptoms were articular, neurological, and sicca manifestations, as detailed in Table 1 and illustrated in Figure 1A. Notably, the regions of abnormal uptake detected by SSTR imaging using 99mTcHYNIC-TOC coincided with symptomatic sites, particularly the joints and salivary glands, as shown in Figure 1B. Furthermore, Matthews correlation analysis confirmed a strong association between abnormal imaging findings and patient-reported symptoms (Table 2). The overlap between symptoms and abnormal imaging findings can be attributed to the role of SST and SSTRs in autoimmune-driven inflammation. During autoimmune inflammation, activated lymphocytes and macrophages exhibit increased expression of SSTRs, which are also found in neoangiogenic vessels, proliferating synovial vessels, and epithelioid cells [35]. This receptor overexpression reflects localized inflammatory activity, particularly in the joints and salivary glands, which is consistent with the symptomatic regions reported by patients. In a few patients, a discrepancy was observed between periorbital symptoms and radiotracer uptake, which may be explained by the variable expression or activation of somatostatin receptors on periorbital fibroblasts. Radiolabelled SST analogues have demonstrated utility in single-photon emission computed tomography (SPECT) and positron emission tomography (PET) for chronic inflammatory diseases, providing clinically relevant insights into disease activity, prognosis, and therapeutic response [26,27]. Molecular imaging’s capability to visualize active inflammation via targeted SSTR expression provides a clear biological basis for symptoms of autoimmune conditions and highlights its diagnostic value in identifying and monitoring complex inflammatory disorders.
Autoantibodies are a defining feature of autoimmune diseases. Experimental evidence has demonstrated their role in silicone-related conditions. For example, a study in mice that spontaneously developed autoimmune diseases following silicone implantation revealed a significant increase in anti-dsDNA antibodies (p < 0.02), rheumatoid factor, and silicone-bound autoantibodies [36]. The ability of silicone to promote autoimmunity may stem from its hydrophobic surface, which alters antigen conformation, leading to immune system recognition of these modified structures and triggering an autoimmune response [37,38]. Additionally, cross-reactivity between silicone and glycosaminoglycans in connective tissue has been proposed as another mechanism of immune activation [13]. Clinical studies further support this link. In a cohort of 57 patients in California, 35% of women with SBIs tested positive for anti-collagen autoantibodies, a prevalence comparable to that observed in patients with erosive arthritis [13]. Similarly, Zandman-Goddard et al. reported elevated levels of 15 distinct autoantibodies in patients with SBIs, regardless of their symptomatology (122 symptomatic vs. 86 asymptomatic women). Among these, anti-SSB/La and anti-collagen II antibodies were the most predominant and were significantly elevated in both groups [39]. Moreover, a large cohort study involving nearly 400,000 women, including 11,800 with SBIs, identified an increased relative risk of 1.24 (95% CI, 1.08–1.41; p = 0.0015) for developing connective tissue disorders [40]. Serologic assessments in women with SBIs have also revealed isolated reductions in complement components C3 and C4 [41]. In the present study, a clear pattern of autoimmune activation was observed, with 33 out of 50 patients (66%) testing positive for at least one autoantibody (Figure 2). Among these, antinuclear antibodies (ANAs) were the most frequently detected (30%), followed by lupus anticoagulant Russell (14%), decreased complement component C3 (7%), and anti-thyroid peroxidase (Anti-TPO) antibodies (5%), among others. These findings are consistent with the broader literature linking silicone exposure to the development of autoantibodies and systemic immune dysregulation, as described in the autoimmune/inflammatory syndrome induced by adjuvants (ASIA). Silicone is thought to act as an immunological adjuvant that facilitates the breakdown of self-tolerance, leading to humoral and cellular immune activation [1]. Importantly, these serologic findings were paralleled by in vivo molecular imaging data: most patients with symptoms demonstrated increased uptake on 99mTc-HYNIC-TOC scintigraphy, particularly in the joints and salivary glands—regions commonly involved in autoimmune processes. This uptake reflects the overexpression of somatostatin receptors (SSTRs) on activated lymphocytes and macrophages, which are known to accumulate in autoimmune inflammation. While SSTR overexpression can occur in other inflammatory conditions, including infectious, neoplastic, and granulomatous diseases [22], the concordance in our cohort between symptom location, autoantibody positivity, and SSTR uptake supports the hypothesis that the immune activation in these patients is autoimmune in nature. Together, these findings underscore the potential of SSTR-targeted scintigraphy as a noninvasive tool to identify organ-specific autoimmune inflammation in patients with SBIs and suspected ASIA, complementing serologic and clinical data in diagnostic evaluation. Seven patients in the cohort underwent surgery, and their baseline and postexplantation data were compared. A key finding was the resolution of abnormal 99mTcHYNIC-TOC uptake in the surgical bed postsurgery. In contrast, findings in other organs—such as the thyroid, joints, and salivary glands—showed no consistent changes among patients, suggesting variable systemic inflammatory responses. These results highlight the role of explantation in reducing localized inflammation, as evidenced by the absence of abnormal uptake in the surgical bed. Given the limit in this subgroup, these findings should be interpreted as preliminary and exploratory; larger prospective studies are needed to validate these postexplantation observations. Previous reports have emphasized that explantation is an important first step in the management of patients with ASIA due to an implant; unfortunately, several women still suffer from ASIA after explantation [42,43]. This variability underscores the complexity of the syndrome and the need for a more comprehensive management strategy. Clinically, the observed findings support the potential use of 99mTcHYNIC-TOC scintigraphy as a valuable tool for assessing organ-specific inflammation. While explantation effectively addresses localized inflammation, the ongoing symptoms in some patients highlight the heterogeneity of ASIA syndrome and its systemic impact. Further research involving larger cohorts and prospective studies is needed to validate these observations and better understand the mechanisms driving organ-specific inflammatory responses postexplantation.
The evidence linking SBIs to ASIA is steadily accumulating. Recognizing this association underscores the importance of identifying women who may have an increased risk of developing this condition [8]. A genetic predisposition to autoimmunity is a plausible factor, with silicone potentially acting as an environmental trigger. However, as such predispositions are not yet easily diagnosable, it is prudent to consider potential risks in defined at-risk groups before deciding on the use of SBIs. Identifying these risk groups can help minimize health complications associated with autoimmune disorders. Furthermore, the associations between SBIs and inflammatory markers highlight the need for robust preoperative and postoperative protocols to assess potential autoimmune risks. Although inflammatory markers alone do not confirm specific immunological diseases, strategic testing combined with interdisciplinary consultations can aid in effective risk management. Collaboration among healthcare providers from different specialties is crucial for addressing the multifaceted risks associated with SBIs. The role of molecular nuclear medicine in this context is particularly significant, as functional imaging can detect in vivo components and phases of diseases, including inflammation-related conditions. This capability extends beyond the morphological abnormalities typically identified by conventional radiological methods, providing a strong rationale for employing nuclear medicine techniques in early diagnosis and treatment planning.
This study provides valuable insights into the role of SSTR scintigraphy as a tool for assessing SST-mediated inflammation and the impact of explantation on inflammatory activity in patients with ASIA syndrome. While previous reports have focused primarily on systemic inflammatory responses in patients with SBIs, our study adds to the literature by offering semiquantitative evidence through SSTR imaging 99mTcHINIC-TOC.
The key strengths of this study include the use of Matthews correlation coefficients to quantify associations between clinical symptoms and scintigraphic findings, as well as paired pre- and postexplantation analyses, which allow for a more nuanced understanding of changes in inflammatory activity. However, several limitations must be acknowledged. The relatively small sample size of 50 patients, coupled with the small postexplantation cohort and retrospective design, restricts the generalizability of the findings and may introduce bias. It is important to note that although all patients presented with clinical symptoms and/or serological markers suggestive of immune dysregulation at the time of scintigraphy, comprehensive data regarding pre-existing autoimmune conditions prior to breast implantation were not consistently available. In a subset of cases, personal or familial autoimmune predispositions were reported, in line with the known risk profiles for ASIA syndrome. However, due to the retrospective nature of the cohort and the referral-based sample, this information was incomplete and represents a limitation. Future prospective studies should aim to systematically document pre-implantation immune status to better delineate causality and risk stratification.
Future prospective studies involving larger cohorts are necessary to validate these results and to further explore the long-term clinical outcomes of explantation in patients with ASIA syndrome. Such investigations could provide a more comprehensive understanding of the relationship between SBIs and SST-mediated inflammation, ultimately enhancing clinical decision making and patient care.

5. Conclusions

This study highlights the potential of 99mTcHYNIC-TOC SSTR scintigraphy as a valuable tool for assessing SST-mediated inflammation and the impact of explantation in patients with ASIA syndrome. This research underscores the importance of multidisciplinary approaches, robust preoperative risk assessments, and innovative imaging techniques in optimizing the management of ASIA syndrome and related autoimmune conditions. Future prospective studies with larger cohorts are warranted to validate these results, elucidate the mechanisms underlying silicone-induced autoimmunity, and explore long-term outcomes of explantation.

Author Contributions

Conceptualization, L.K.A., and J.N.R.; methodology L.K.A. and S.M.; software S.M.; validation S.R. (Sara Ramirez) and C.V.; formal analysis, L.K.A. and S.R. (Sara Ramirez); investigation L.K.A., S.R. (Sara Ramirez), and S.R. (Sebastian Rojas); resources, J.N.R., S.R. (Sara Ramirez), and S.R. (Sebastian Rojas) writing—original draft preparation, L.K.A.; writing—review and editing, J.N.R. and L.K.A. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The study was approved by the Institutional Review Board of UNISANITAS (protocol code 2293-23, 28 August 2023).

Informed Consent Statement

Patient consent was waived due to the retrospective nature of the analysis.

Data Availability Statement

The original contributions presented in this study are included in the article. Further inquiries can be directed to the corresponding author.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Shoenfeld, Y.; Agmon-Levin, N. ‘ASIA’—Autoimmune/inflammatory syndrome induced by adjuvants. J. Autoimmun. 2011, 36, 4–8. [Google Scholar] [CrossRef]
  2. Shoenfeld, Y.; Zandman-Goddard, G.; Stojanovich, L.; Cutolo, M.; Amital, H.; Levy, Y.; Abu-Shakra, M.; Barzilai, O.; Berkun, Y.; Blank, M. The mosaic of autoimmunity: Hormonal and environmental factors involved in autoimmune diseases 2008. IMAJ 2008, 10, 8–12. [Google Scholar]
  3. Agmon-Levin, N.; Paz, Z.; Israeli, E.; Shoenfeld, Y. Vaccines and autoimmunity. Nat. Rev. Rheumatol. 2009, 5, 648–652. [Google Scholar] [CrossRef] [PubMed]
  4. Israeli, E.; Agmon-Levin, N.; Blank, M.; Shoenfeld, Y. Adjuvants and autoimmunity. Lupus 2009, 18, 1217–1225. [Google Scholar] [CrossRef] [PubMed]
  5. Hornung, V.; Bauernfeind, F.; Halle, A.; Samstad, E.O.; Kono, H.; Rock, K.L.; Fitzgerald, K.A.; Latz, E. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat. Immunol. 2008, 9, 847–856. [Google Scholar] [CrossRef]
  6. Bar-Meir, E.; Eherenfeld, M.; Shoenfeld, Y. Silicone gel breast implants and connective tissue disease--a comprehensive review. Autoimmunity 2003, 36, 193–197. [Google Scholar] [CrossRef]
  7. Soriano, A.; Butnaru, D.; Shoenfeld, Y. Long-term inflammatory conditions following silicone exposure: The expanding spectrum of the autoimmune/inflammatory syndrome induced by adjuvants (ASIA). Clin. Exp. Rheumatol. 2014, 32, 151–154. [Google Scholar] [PubMed]
  8. Goren, I.; Segal, G.; Shoenfeld, Y. Autoimmune/inflammatory syndrome induced by adjuvant (ASIA) evolution after silicone implants. Who is at risk? Clin. Rheumatol. 2015, 34, 1661–1666. [Google Scholar] [CrossRef] [PubMed]
  9. Rohrich, R.J.; Adams, W.P., Jr.; Beran, S.J.; Rathakrishnan, R.; Griffin, J.; Robinson, J.B., Jr.; Kenkel, J.M. An analysis of silicone gel-filled breast implants: Diagnosis and failure rates. Plast. Reconstr. Surg. 1998, 102, 2304–2308. [Google Scholar] [CrossRef]
  10. Yu, L.T.; Latorre, G.; Marotta, J.; Batich, C.; Hardt, N.S. In vitro measurement of silicone bleed from breast implants. Plast. Reconstr. Surg. 1996, 97, 756–764. [Google Scholar] [CrossRef]
  11. Kivity, S.; Katz, M.; Langevitz, P.; Eshed, I.; Olchovski, D.; Barzilai, A. Autoimmune syndrome induced by adjuvants (ASIA) in the Middle East: Morphea following silicone implantation. Lupus 2012, 21, 136–139. [Google Scholar] [CrossRef] [PubMed]
  12. Wolfram, D.; Rabensteiner, E.; Grundtman, C.; Böck, G.; Mayerl, C.; Parson, W.; Almanzar, G.; Hasenöhrl, C.; Piza-Katzer, H.; Wick, G. T regulatory cells and TH17 cells in peri-silicone implant capsular fibrosis. Plast. Reconstr. Surg. 2012, 129, 327e–337e. [Google Scholar] [CrossRef] [PubMed]
  13. Teuber, S.S.; Rowley, M.J.; Yoshida, S.H.; Ansari, A.A.; Gershwin, M.E. Anti-collagen autoantibodies are found in women with silicone breast implants. J. Autoimmun. 1993, 6, 367–377. [Google Scholar] [CrossRef]
  14. Schaefer, C.J.; Wooley, P.H. The influence of silicone implantation on murine lupus in MRL lpr/lpr mice. J. Rheumatol. 1999, 26, 2215–2221. [Google Scholar] [PubMed]
  15. Cohen Tervaert, J.W. Autoinflammatory/autoimmunity syndrome induced by adjuvants (ASIA; Shoenfeld’s syndrome): A new flame. Autoimmun. Rev. 2018, 7, 1259–1264. [Google Scholar] [CrossRef]
  16. Caravantes-Cortes, M.I.; Roldan-Valadez, E.; Zwojewski-Martinez, R.D.; Salazar-Ruiz, S.Y.; Carballo-Zarate, A.A. Breast Prosthesis Syndrome: Pathophysiology and Management Algorithm. Aesthetic Plast. Surg. 2020, 44, 1423–1437. [Google Scholar] [CrossRef]
  17. Alijotas-Reig, J.; Esteve-Valverde, E.; Gil-Aliberas, N.; Garcia-Gimenez, V. Autoimmune/inflammatory syndrome induced by adjuvants-ASIA-related to biomaterials: Analysis of 45 cases and comprehensive review of the literature. Immunol. Res. 2018, 66, 120–140. [Google Scholar] [CrossRef]
  18. Abbruzzese, B.; Zubal, G.; Behr, S.; Ralph, D.; Shuping, J.; Colborn, D.; Kissling, A.; Sanders, J.; DeMeo, D.; Hartings, C.; et al. Macrophage CD206 Receptor Targeting with 99m Tc-Tilmanocept Permits Specific Quantitative Diagnostic Imaging of Active Rheumatoid Arthritis (RA) and id Differentiated from Osteoarthritis (OA). J. Nucl. Med. 2017, 58, 303. [Google Scholar]
  19. Signore, A.; Chianelli, M.; Annovazzi, A.; Bonanno, E.; Spagnoli, L.G.; Pozzilli, P.; Pallone, F.; Biancone, L. 123I-interleukin-2 scintigraphy for in vivo assessment of intestinal mononuclear cell infiltration in Crohn’s disease. J. Nucl. Med. 2000, 41, 242–249. [Google Scholar]
  20. Namavari, M.; Chang, Y.F.; Kusler, B.; Yaghoubi, S.; Mitchell, B.S.; Gambhir, S.S. Synthesis of 2’-deoxy-2’-[18F]fluoro-9-β-D-arabinofuranosylguanine: A novel agent for imaging T-cell activation with PET. Mol. Imaging Biol. 2011, 13, 812–818. [Google Scholar] [CrossRef]
  21. Anzola, L.K.; Rivera, J.N.; Dierckx, R.A.; Lauri, C.; Valabrega, S.; Galli, F.; Moreno Lopez, S.; Glaudemans, A.W.J.M.; Signore, A. Value of Somatostatin Receptor Scintigraphy with 99mTc-HYNIC-TOC in Patients with Primary Sjögren Syndrome. J. Clin. Med. 2019, 8, 763. [Google Scholar] [CrossRef] [PubMed]
  22. Anzola, L.K.; Glaudemans, A.W.J.M.; Dierckx, R.A.J.O.; Martinez, F.A.; Moreno, S.; Signore, A. Somatostatin receptor imaging by SPECT and PET in patients with chronic inflammatory disorders: A systematic review. Eur. J. Nucl. Med. Mol. Imaging 2019, 46, 2496–2513. [Google Scholar] [CrossRef] [PubMed]
  23. Campagna, G.; Anzola, L.K.; Varani, M.; Lauri, C.; Gentiloni Silveri, G.; Chiurchioni, L.; Spinelli, F.R.; Priori, R.; Conti, F.; Signore, A. Imaging Activated-T-Lymphocytes in the Salivary Glands of Patients with Sjögren’s Syndrome by 99mTc-Interleukin-2: Diagnostic and Therapeutic Implications. J. Clin. Med. 2022, 11, 4368. [Google Scholar] [CrossRef]
  24. Narayanan, S.; Kunz, P.L. Role of somatostatin analogues in the treatment of neuroendocrine tumors. J. Natl. Compr. Cancer Netw. 2015, 13, 109–117. [Google Scholar] [CrossRef]
  25. Duet, M.; Lioté, F. Somatostatin and somatostatin analog scintigraphy: Any benefits for rheumatology patients? Joint Bone Spine 2004, 71, 530–535. [Google Scholar] [CrossRef] [PubMed]
  26. Cascini, G.L.; Cuccurullo, V.; Mansi, L. The non tumour uptake of (111) In-octreotide creates new clinical indications in benign diseases, but also in oncology. Q. J. Nucl. Med. Mol. Imaging 2010, 54, 24–36. [Google Scholar]
  27. Breeman, W.A.; de Blois, E.; Sze Chan, H.; Konijnenberg, M.; Kwekkeboom, D.J.; Krenning, E.P. (68)Ga-labeled DOTA-peptides and (68)Ga-labeled radiopharmaceuticals for positron emission tomography: Current status of research, clinical applications, and future perspectives. Semin. Nucl. Med. 2011, 41, 314–321. [Google Scholar] [CrossRef]
  28. Vanhagen, P.M.; Markusse, H.M.; Lamberts, S.W.; Kwekkeboom, D.J.; Reubi, J.C.; Krenning, E.P. Somatostatin receptor imaging. The presence of somatostatin receptors in rheumatoid arthritis. Arthritis Rheum. 1994, 37, 1521–1527. [Google Scholar] [CrossRef]
  29. Sun, H.; Jiang, X.F.; Wang, S.; Chen, H.Y.; Sun, J.; Li, P.Y.; Ning, G.; Zhao, Y.J. (99m)Tc-HYNIC-TOC scintigraphy in evaluation of active Graves’ ophthalmopathy (GO). Endocrine 2007, 31, 305–310. [Google Scholar] [CrossRef]
  30. Anzola-Fuentes, L.K.; Chianelli, M.; Galli, F.; Glaudemans, A.W.; Martin Martin, L.; Todino, V.; Migliore, A.; Signore, A. Somatostatin receptor scintigraphy in patients with rheumatoid arthritis and secondary Sjögren’s syndrome treated with Infliximab: A pilot study. EJNMMI Res. 2016, 6, 49. [Google Scholar] [CrossRef]
  31. Wolfe, F.; Clauw, D.J.; Fitzcharles, M.A.; Goldenberg, D.L.; Häuser, W.; Katz, R.L.; Mease, P.J.; Russell, A.S.; Russell, I.J.; Walitt, B. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin. Arthritis Rheum. 2016, 46, 319–329. [Google Scholar] [CrossRef] [PubMed]
  32. Andreoli, L.; Tincani, A. Undifferentiated connective tissue disease, fibromyalgia and the environmental factors. Curr. Opin. Rheumatol. 2017, 29, 355–360. [Google Scholar] [CrossRef] [PubMed]
  33. Teuber, S.S.; Howell, L.P.; Yoshida, S.H.; Gershwin, M.E. Remission of sarcoidosis following removal of silicone gel breast implants. Int. Arch. Allergy Immunol. 1994, 105, 404–407. [Google Scholar] [CrossRef] [PubMed]
  34. Watad, A.; Rosenberg, V.; Tiosano, S.; Cohen Tervaert, J.W.; Yavne, Y.; Shoenfeld, Y.; Shalev, V.; Chodick, G.; Amital, H. Silicone breast implants and the risk of autoimmune/rheumatic disorders: A real-world analysis. Int. J. Epidemiol. 2018, 47, 1846–1854. [Google Scholar] [CrossRef]
  35. Virgolini, I.; Pangerl, T.; Bischof, C.; Smith-Jones, P.; Peck-Radosavljevic, M. Somatostatin receptor subtype expression in human tissues: A prediction for diagnosis and treatment of cancer? Eur. J. Clin. Invest. 1997, 27, 645–647. [Google Scholar] [CrossRef]
  36. Nair, N.; Pilakka-Kanthikeel, S.; Saiyed, Z.; Yndart, A.; Nair, M. Silicone nanoparticles do not induce immune responses by naïve human peripheral blood mononuclear cells: Implications in breast implants. Plast. Reconstr. Surg. 2012, 130, 128e–137e. [Google Scholar] [CrossRef]
  37. Schaefer, C.J.; Lawrence, W.D.; Wooley, P.H. Influence of long term silicone implantation on type II collagen induced arthritis in mice. Ann. Rheum. Dis. 1999, 58, 503–509. [Google Scholar] [CrossRef]
  38. Kossovsky, N.; Freiman, C.J. Silicone breast implant pathology. Clinical data and immunologic consequences. Arch. Pathol. Lab. Med. 1994, 118, 686–693. [Google Scholar]
  39. Zandman-Goddard, G.; Blank, M.; Ehrenfeld, M.; Gilburd, B.; Peter, J.; Shoenfeld, Y. A comparison of autoantibody production in asymptomatic and symptomatic women with silicone breast implants. J. Rheumatol. 1999, 26, 73–77. [Google Scholar]
  40. Hennekens, C.H.; Lee, I.M.; Cook, N.R.; Hebert, P.R.; Karlson, E.W.; LaMotte, F.; Manson, J.E.; Buring, J.E. Self-reported breast implants and connective-tissue diseases in female health professionals. A retrospective cohort study. JAMA 1996, 275, 616–621. [Google Scholar] [CrossRef]
  41. Karlson, E.W.; Lee, I.M.; Cook, N.R.; Buring, J.E.; Hennekens, C.H.; Bloch, K.J. Serologic evaluations of women exposed to breast implants. J. Rheumatol. 2001, 28, 1523–1530. [Google Scholar] [PubMed]
  42. Colaris, M.J.L.; de Boer, M.; van der Hulst, R.R.; Cohen Tervaert, J.W. Two hundreds cases of ASIA syndrome following silicone implants: A comparative study of 30 years and a review of current literature. Immunol. Res. 2017, 65, 120–128. [Google Scholar] [CrossRef] [PubMed]
  43. de Boer, M.; Colaris, M.; van der Hulst, R.R.W.J.; Cohen Tervaert, J.W. Is explantation of silicone breast implants useful in patients with complaints? Immunol. Res. 2017, 65, 25–36. [Google Scholar] [CrossRef] [PubMed]
Jcm 14 04141 g001
Figure 1. Frequency of symptoms and findings on 99mTcHYNIC-TOC scintigraphy among patients with SBIs and autoimmune symptoms. (A) Symptoms. (B) Positive findings on 99mTcHYNIC-TOC scintigraphy.
Figure 1. Frequency of symptoms and findings on 99mTcHYNIC-TOC scintigraphy among patients with SBIs and autoimmune symptoms. (A) Symptoms. (B) Positive findings on 99mTcHYNIC-TOC scintigraphy.
Jcm 14 04141 g001
Jcm 14 04141 g002
Figure 2. Antibody distribution in patients with silicone implant-associated autoimmunity.
Figure 2. Antibody distribution in patients with silicone implant-associated autoimmunity.
Jcm 14 04141 g002
Jcm 14 04141 g003
Figure 3. Semiquantitative analysis of pre -and postsurgical 99mTc HYNIC-TOC scintigraphy.
Figure 3. Semiquantitative analysis of pre -and postsurgical 99mTc HYNIC-TOC scintigraphy.
Jcm 14 04141 g003
Jcm 14 04141 g004aJcm 14 04141 g004bJcm 14 04141 g004c
Figure 4. 99mTc HYNIC-TOC scintigraphy showing abnormal uptake of the radiotracer surrounding the breast implants (a) and knees, elbows, carpal joints, and ankles (c). Postexplantation scintigraphy showing no uptake in surgical bed in the same patient (b).
Figure 4. 99mTc HYNIC-TOC scintigraphy showing abnormal uptake of the radiotracer surrounding the breast implants (a) and knees, elbows, carpal joints, and ankles (c). Postexplantation scintigraphy showing no uptake in surgical bed in the same patient (b).
Jcm 14 04141 g004aJcm 14 04141 g004bJcm 14 04141 g004c
Table 1. Demographic characteristics (n = 50).
Table 1. Demographic characteristics (n = 50).
Characteristics aTotal, n (%)
n = 50
Age in years44.50 (37.00–51.00)
Age group     
   20–301 (2.00%)
   30–4014 (28.00%)
   40–5019 (38.00%)
   50–6012 (24.00%)
   ≥ 604 (8.00%)
Consultation symptoms     
   Neurological symptoms30 (60.00%)
   Carpal38 (76.00%)
   Elbows22 (44.00%)
   Knees35 (70.00%)
   Sicca30 (60.00%)
   Periorbital fat8 (16.00%)
   Thyroid gland1 (2.00%)
Scintigraphic findings     
   Carpal39 (78.00%)
   Elbows28 (56.00%)
   Knees37 (74.00%)
   Salivary glands30 (60.00%)
   Thyroid gland12 (24.00%)
Notes: a Data are presented as the mean (SD) for continuous measures, and n (%) for categorical measures.
Table 2. Matthews correlation coefficients between reported symptoms and scintigraphic findings.
Table 2. Matthews correlation coefficients between reported symptoms and scintigraphic findings.
Characteristics aGammagraphic
Findings Negative		Gammagraphic Findings PositiveTotalϕ Matthews’s Correlationp Value
n = 11n = 39n = 50
Carpal symptoms 0.72<0.001
      Negative9 (82%)3 (8%)12 (24%)
      Positive2 (18%)36 (92%)38 (76%)
n = 22n = 28n = 50
Elbow symptoms 0.79<0.001
      Negative22 (100%)6 (21%)28 (56%)
      Positive0 (0%)22 (79%)22 (44%)
n = 13n = 37n = 50
Knee symptoms 0.81<0.001
      Negative12 (92%)3 (8%)15 (30%)
      Positive1 (8%)34 (92%)35 (70%)
n = 49n = 1n = 50
Periorbitary symptoms 0.330.37
      Negative42 (86%)0 (0%)42 (84%)
      Positive7 (14%)1 (100%)8 (16%)
n = 19n = 31n = 50
Salivary glands symptoms 0.92<0.001
      Negative18 (95%)1 (3%)19 (38%)
      Positive1 (5%)30 (97%)31 (62%)
a Data are presented as n (%) for categorical measures.
Table 3. Frequency of organ improvement under 99mTcHYNIC-TOC in patients who underwent explantation.
Table 3. Frequency of organ improvement under 99mTcHYNIC-TOC in patients who underwent explantation.
Characteristics aImprovment
n = 7
     Implants7 (100%)
     Thyroid1 (14.28%)
     Joints3 (42.85%)
     Salivary glands3 (42.85%)
     Periorbitary fat2 (28.57%)
a Data are presented as n (%) for categorical measures.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Anzola, L.K.; Ramirez, S.; Moreno, S.; Vargas, C.; Rojas, S.; Rivera, J.N. Somatostatin Receptor Scintigraphy in Autoimmune Syndrome Induced by Silicone Breast Implants: Pre- and Postexplantation Findings. J. Clin. Med. 2025, 14, 4141. https://doi.org/10.3390/jcm14124141

AMA Style

Anzola LK, Ramirez S, Moreno S, Vargas C, Rojas S, Rivera JN. Somatostatin Receptor Scintigraphy in Autoimmune Syndrome Induced by Silicone Breast Implants: Pre- and Postexplantation Findings. Journal of Clinical Medicine. 2025; 14(12):4141. https://doi.org/10.3390/jcm14124141

Chicago/Turabian Style

Anzola, Luz Kelly, Sara Ramirez, Sergio Moreno, Camilo Vargas, Sebastian Rojas, and José Nelson Rivera. 2025. "Somatostatin Receptor Scintigraphy in Autoimmune Syndrome Induced by Silicone Breast Implants: Pre- and Postexplantation Findings" Journal of Clinical Medicine 14, no. 12: 4141. https://doi.org/10.3390/jcm14124141

APA Style

Anzola, L. K., Ramirez, S., Moreno, S., Vargas, C., Rojas, S., & Rivera, J. N. (2025). Somatostatin Receptor Scintigraphy in Autoimmune Syndrome Induced by Silicone Breast Implants: Pre- and Postexplantation Findings. Journal of Clinical Medicine, 14(12), 4141. https://doi.org/10.3390/jcm14124141

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop